Temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales: Is it a feasible option? - 01/05/26
Highlights |
• | Evidence pertaining to temocillin in non-urinary AmpC infections is limited. |
• | This study reports on real-life use of temocillin in digestive and respiratory infections. |
• | Clinical cure was achieved in all patients at Day 28. |
• | No relapse or infection-related death occurred. |
• | Temocillin may in selected cases be considered as a carbapenem-sparing option. |
Abstract |
Background |
Infections due to AmpC-producing Enterobacterales represent an increasing therapeutic challenge. Third-generation cephalosporins may select resistant mutants, inducing clinicians to use cefepime or carbapenems and thereby contributing to carbapenem resistance. While temocillin is a narrow-spectrum beta-lactam stable against AmpC enzymes, evidence of its impact in non-urinary tract infections remains limited.
Methods |
We conducted a retrospective study of adult patients treated with temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales between 2016 and 2021. Clinical, microbiological and therapeutic data were collected. The primary outcome was treatment failure within twenty-eight days.
Results |
Six patients were included, with a median age of sixty-one years; three required intensive care. Infection sites were digestive or respiratory. All patients had achieved clinical cure by day twenty-eight, without recurrence, infection-related mortality, or adverse events.
Conclusion |
Having led to favorable outcomes, temocillin may represent a carbapenem-sparing option when in vitro susceptibility is confirmed. These findings call for further evaluation in larger prospective clinical studies.
Le texte complet de cet article est disponible en PDF.Keywords : Temocillin, AmpC enzymes, Antibiotic, Infection, Carbapenem-sparing agent
Plan
Vol 56 - N° 3
Article 105257- avril 2026 Retour au numéro
Article précédent
- Increasing rates of Chlamydia trachomatis infection in Alberta, Saskatchewan, and Manitoba compared to Canada overall, between 1991 and 2022
- Maria Arango-Uribe, Rotem Keynan, Zipporah Gitau, Camilo Suarez-Ariza, Angela Copete, Mariana Herrera, Camila Oda, Ameeta E. Singh, Stuart Skinner, Cara Spence, Lauren J. MacKenzie, Ken Kasper, Laurie Ireland, Jared Bullard, David Alexander, Diana Marin, Lucelly Lopez, Margaret Haworth-Brockman, Yoav Keynan, Zulma Vanessa Rueda
- Antibiotic tolerance and safety in infective endocarditis: A focus on older patients
- Capucine RICHARD, Sylvain GAUTIER, Pierre BOISSON DE CHAZOURNES, Karim JAFFAL, Ségolène PERRINEAU, Valérie SIVADON TARDY, Cyril CHARRON, Nicolas MANSENCAL, Aurélien DINH, Marion PÉPIN, on behalf of the endocarditis team of A. Paré Hospital
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?